Therefore, this study aimed to investigate whether the monoclonal IL-1β inhibitor canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes according to the timing of its use in patients with Still’s disease in terms of different lines of biologic treatment. This evidence concerns the gene IL1B and systemic-onset juvenile idiopathic arthritis.